We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tissue Regenix Group Plc | LSE:TRX | London | Ordinary Share | GB00BNTXR104 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.70 | -2.76% | 59.80 | 61.00 | 62.00 | 61.50 | 61.50 | 61.50 | 44,244 | 16:35:15 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 24.48M | -2.7M | -0.0382 | -16.10 | 43.4M |
TIDMTRX
RNS Number : 2015Q
Tissue Regenix Group PLC
08 September 2017
Tissue Regenix Group plc
Notice of Interim Results and Capital Markets Day
Leeds, 8 September 2017 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company, today gives notice that it will announce its interim results for the six months ending 31 June 2017, on Thursday 28 September 2017.
The Group will also host a Capital Markets Day in London on Thursday 12 October where it will provide an update on business activities and the integration of CellRight Technologies, with presentations from top level UK and US management.
For more Information:
Tissue Regenix Group plc Tel: 0330 430 Caitlin Pearson, Corporate Communications 3073 Director =========================================== ============== Jefferies International Ltd Tel: 020 7029 Simon Hardy / Christopher Binks 8000 FTI Consulting Tel: 020 3727 Brett Pollard/ Mo Noonan/ Rob 1000 Winder =========================================== ==============
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL(R) ') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.
In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies(R) , a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORZMGGLKRVGNZG
(END) Dow Jones Newswires
September 08, 2017 02:00 ET (06:00 GMT)
1 Year Tissue Regenix Chart |
1 Month Tissue Regenix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions